Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03929744 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3502970 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 133
- Enrollment target
NCT03929744 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 133 participants.
The verdict
NCT03929744, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 133 participants
- Enrollment target
Study Summary
The main purposes of this study are to determine: * The safety of LY3502970 and any side effects that might be associated with it. * How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it. This study has 5 parts (A, B, C, D, and E). Parts A and D involve a single dose of LY3502970 and will last about 15 days. Part B and E involve multiple doses of LY3502970 and will last about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days. Each participant will enroll in only one part. Screening must be completed within 28 days before study start. This study is for research purposes only, and is not intended to treat any medical condition.
Interventions
- DRUG Placebo
- DRUG Midazolam
- DRUG Simvastatin
- DRUG Atorvastatin
- DRUG LY3502970
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2019-06-12 |
| Est. Completion | 2020-11-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03929744
The ClinicalTrials.gov registry entry for NCT03929744 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03929744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03929744 about?
NCT03929744 is a clinical study titled "A Study of LY3502970 in Healthy Participants". The main purposes of this study are to determine: * The safety of LY3502970 and any side effects that might be associated with it. * How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it. This study has 5 parts (A, B, C, D, and E). Parts A and D involve a sin...
What is the current status of trial NCT03929744?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 133 participants. The study started on 2019-06-12. Estimated completion is 2020-11-02.
What interventions are being tested in trial NCT03929744?
The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), Simvastatin (DRUG), Atorvastatin (DRUG), LY3502970 (DRUG).
Who is sponsoring clinical trial NCT03929744?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.